MicroRNA-34a Encapsulated in Hyaluronic Acid Nanoparticles Induces Epigenetic Changes with Altered Mitochondrial Bioenergetics and Apoptosis in Non-Small-Cell Lung Cancer Cells

[1]  P. Barnes,et al.  Oxidative stress dependent microRNA-34a activation via PI3Kα reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells , 2016, Scientific Reports.

[2]  Michael Schwarz,et al.  Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer. , 2016, Cancer research.

[3]  P. Shah,et al.  Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Chunling Ma,et al.  CpG methylation patterns of human mitochondrial DNA , 2016, Scientific Reports.

[5]  J. V. Moran,et al.  p53 genes function to restrain mobile elements , 2016, Genes & development.

[6]  Lu Xiao-jie,et al.  LINE-1 in cancer: multifaceted functions and potential clinical implications , 2015, Genetics in Medicine.

[7]  B. Sarmento,et al.  Combinatorial-Designed Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles for Encapsulation and Delivery of Lipid-Modified Platinum Derivatives in Wild-Type and Resistant Non-Small-Cell Lung Cancer Cells. , 2015, Molecular pharmaceutics.

[8]  S. Lindén,et al.  IL-4 Protects the Mitochondria Against TNFα and IFNγ Induced Insult During Clearance of Infection with Citrobacter rodentium and Escherichia coli , 2015, Scientific Reports.

[9]  Guoyu Yang,et al.  Knockdown of PKM2 induces apoptosis and autophagy in human A549 alveolar adenocarcinoma cells. , 2015, Molecular medicine reports.

[10]  S. David,et al.  DNMT1 and Cancer: An Electrifying Link. , 2015, Chemistry & biology.

[11]  Michael S. Goldberg,et al.  Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer , 2015, Molecular Cancer Therapeutics.

[12]  P. Lambin,et al.  How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. , 2015, Mutation research. Reviews in mutation research.

[13]  R. Rahbari,et al.  LINE-1 Retrotransposons and Their Role in Cancer , 2015 .

[14]  H. Byun,et al.  Analysis of pollutant-induced changes in mitochondrial DNA methylation. , 2015, Methods in molecular biology.

[15]  G. Trooskens,et al.  Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. , 2014, The Journal of nutritional biochemistry.

[16]  N. Rothman,et al.  Pooled Analysis of Mitochondrial DNA Copy Number and Lung Cancer Risk in Three Prospective Studies , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[17]  Hyung Gyun Kim,et al.  Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. , 2014, Free radical biology & medicine.

[18]  Robert Langer,et al.  Small RNA combination therapy for lung cancer , 2014, Proceedings of the National Academy of Sciences.

[19]  Bin Tean Teh,et al.  Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer , 2014, eLife.

[20]  A. Procopio,et al.  MitomiRs in human inflamm-aging: A hypothesis involving miR-181a, miR-34a and miR-146a , 2014, Experimental Gerontology.

[21]  D. Santini,et al.  BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management , 2014, BioMed research international.

[22]  X J Li,et al.  MicroRNA-34a: a potential therapeutic target in human cancer , 2014, Cell Death and Disease.

[23]  H. Byun,et al.  Morphine Induces Redox-Based Changes in Global DNA Methylation and Retrotransposon Transcription by Inhibition of Excitatory Amino Acid Transporter Type 3–Mediated Cysteine Uptake , 2014, Molecular Pharmacology.

[24]  Can Liu,et al.  The microRNA miR-34a Inhibits Non-Small Cell Lung Cancer (NSCLC) Growth and the CD44hi Stem-Like NSCLC Cells , 2014, PloS one.

[25]  T. Speed,et al.  A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression , 2014, Genes & development.

[26]  Liang Zhou,et al.  MicroRNA-34a Targets Bcl-2 and Sensitizes Human Hepatocellular Carcinoma Cells to Sorafenib Treatment , 2014, Technology in cancer research & treatment.

[27]  K. Ramos,et al.  The promise and failures of epigenetic therapies for cancer treatment. , 2014, Cancer treatment reviews.

[28]  S. Sengupta,et al.  Comparative analysis of human mitochondrial methylome show distinct patterns of epigenetic regulation in mitochondria , 2014, Molecular Cytogenetics.

[29]  S. Anant,et al.  DNA Methyltransferases: A Novel Target for Prevention and Therapy , 2013, Front. Oncol..

[30]  P. Pölönen,et al.  Role of the Keap1-Nrf2 pathway in cancer. , 2014, Advances in cancer research.

[31]  Arun K Iyer,et al.  In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[32]  A. Weeraratna,et al.  Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. , 2013, The Journal of clinical investigation.

[33]  Arun K Iyer,et al.  Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer , 2013, Molecular therapy. Nucleic acids.

[34]  Vincenzo Riso,et al.  The Control Region of Mitochondrial DNA Shows an Unusual CpG and Non-CpG Methylation Pattern , 2013, DNA research : an international journal for rapid publication of reports on genes and genomes.

[35]  M. Nitti,et al.  Role of Glutathione in Cancer Progression and Chemoresistance , 2013, Oxidative medicine and cellular longevity.

[36]  Arun K Iyer,et al.  Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. , 2013, Biomaterials.

[37]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[38]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[39]  Shaomin Li,et al.  Soluble oligomers of amyloid-β cause changes in redox state, DNA methylation, and gene transcription by inhibiting EAAT3 mediated cysteine uptake. , 2013, Journal of Alzheimer's disease : JAD.

[40]  M. Kurtoğlu,et al.  Targeting cisplatin-resistant human tumor cells with metabolic inhibitors , 2013, Cancer Chemotherapy and Pharmacology.

[41]  L. Hou,et al.  Effects of airborne pollutants on mitochondrial DNA Methylation , 2013, Particle and Fibre Toxicology.

[42]  H. Manev,et al.  Effect of aging on 5-hydroxymethylcytosine in brain mitochondria , 2012, Neurobiology of Aging.

[43]  R. Knight,et al.  NRF2 and p53: Januses in cancer? , 2012, Oncotarget.

[44]  G. Barrera.  Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy , 2012, ISRN oncology.

[45]  Hsien-Da Huang,et al.  TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. , 2012, Cell reports.

[46]  M. Herlyn,et al.  Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. , 2012, Cancer cell.

[47]  H. Manev,et al.  Effect of valproic acid on mitochondrial epigenetics. , 2012, European journal of pharmacology.

[48]  M. Sporn,et al.  NRF2 and cancer: the good, the bad and the importance of context , 2012, Nature Reviews Cancer.

[49]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[50]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[51]  B. He,et al.  Association of Mitochondrial DNA Variations with Lung Cancer Risk in a Han Chinese Population from Southwestern China , 2012, PloS one.

[52]  Sanjeev Das,et al.  PGC-1α, a key modulator of p53, promotes cell survival upon metabolic stress. , 2011, Molecular cell.

[53]  Hao Liu,et al.  Mitochondrial DNA Content Varies with Pathological Characteristics of Breast Cancer , 2011, Journal of oncology.

[54]  Xueyuan Bai,et al.  miR-335 and miR-34a Promote renal senescence by suppressing mitochondrial antioxidative enzymes. , 2011, Journal of the American Society of Nephrology : JASN.

[55]  Nicholas B. Griner,et al.  Mitochondrial Dysfunction Impairs Tumor Suppressor p53 Expression/Function* , 2011, The Journal of Biological Chemistry.

[56]  Harshini Sarojini,et al.  Increased expression of miR-34a and miR-93 in rat liver during aging, and their impact on the expression of Mgst1 and Sirt1 , 2011, Mechanisms of Ageing and Development.

[57]  J. Estrela,et al.  Glutathione in Cancer Cell Death , 2011, Cancers.

[58]  K. O'Byrne,et al.  The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer , 2011, Cancers.

[59]  Shirley M. Taylor,et al.  DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria , 2011, Proceedings of the National Academy of Sciences.

[60]  M. Kuo,et al.  Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy , 2010, Metal-based drugs.

[61]  Sanjay Gupta,et al.  Epigenetics and cancer. , 2010, Journal of applied physiology.

[62]  M. Ogris.  Nucleic acid therapeutics: concepts for targeted delivery to solid tumors. , 2010, Therapeutic delivery.

[63]  Evan E. Eichler,et al.  LINE-1 Retrotransposition Activity in Human Genomes , 2010, Cell.

[64]  W. Hou,et al.  Regulation of Mitochondrial Apoptotic Events by p53-mediated Disruption of Complexes between Antiapoptotic Bcl-2 Members and Bim* , 2010, The Journal of Biological Chemistry.

[65]  H. Hermeking.  The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[66]  M. Dewhirst,et al.  Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. , 2010, Future oncology.

[67]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[68]  A. Levine,et al.  p53 responsive elements in human retrotransposons , 2009, Oncogene.

[69]  J. Cidlowski,et al.  Apoptosis and glutathione: beyond an antioxidant , 2009, Cell Death and Differentiation.

[70]  U. Moll,et al.  The mitochondrial p53 pathway. , 2009, Biochimica et biophysica acta.

[71]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[72]  D. Aggarwal,et al.  Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. , 2009, Biophysical journal.

[73]  Chun-Ming Tsai,et al.  Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy. , 2008, Interactive cardiovascular and thoracic surgery.

[74]  J. Enríquez,et al.  Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels. , 2008, The Biochemical journal.

[75]  E. Condom,et al.  Altered expression of 12S/MT‐RNR1, MT‐CO2/COX2, and MT‐ATP6 mitochondrial genes in prostate cancer , 2008, The Prostate.

[76]  J. Cidlowski,et al.  Glutathione Depletion Is Necessary for Apoptosis in Lymphoid Cells Independent of Reactive Oxygen Species Formation* , 2007, Journal of Biological Chemistry.

[77]  Y. Bang,et al.  Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy , 2007, Journal of Molecular Medicine.

[78]  Moshe Oren,et al.  Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. , 2007, Molecular cell.

[79]  Zdenko Herceg,et al.  Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis , 2007, Molecular oncology.

[80]  T. Russo,et al.  p53 Suppresses the Nrf2-dependent Transcription of Antioxidant Response Genes* , 2006, Journal of Biological Chemistry.

[81]  F. Fontanesi,et al.  Assembly of mitochondrial cytochrome c-oxidase, a complicated and highly regulated cellular process. , 2006, American journal of physiology. Cell physiology.

[82]  A. Chatterjee,et al.  Mitochondrial DNA mutations in human cancer , 2006, Oncogene.

[83]  O. J. Semmes,et al.  Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cells , 2006, Cancer Cell International.

[84]  Angel Ortega,et al.  Glutathione in Cancer Biology and Therapy , 2006, Critical reviews in clinical laboratory sciences.

[85]  R. Sabirov,et al.  Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase , 2005, Cell Death and Differentiation.

[86]  G. Balendiran,et al.  The role of glutathione in cancer , 2004, Cell biochemistry and function.

[87]  O. J. Semmes,et al.  Retrotransposition-Competent Human LINE-1 Induces Apoptosis in Cancer Cells With Intact p53 , 2004, Journal of biomedicine & biotechnology.

[88]  M. Robert,et al.  DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells , 2003, Nature Genetics.

[89]  Peng Huang,et al.  Mitochondrial defects in cancer , 2002, Molecular Cancer.

[90]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[91]  J. Robert,et al.  Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells. , 2002, Biochemical pharmacology.

[92]  R. von Harsdorf,et al.  p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c‐independent apoptosis blocked by Bcl‐2 , 1999, The EMBO journal.

[93]  R. Cardiff,et al.  Expression of LINE‐1 retrotransposons in human breast cancer , 1994, Cancer.

[94]  F. Sanger,et al.  Sequence and organization of the human mitochondrial genome , 1981, Nature.

[95]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.